Trial
NCT03216486
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Ultragenyx Pharmaceutical Inc
Collaborators
Mereo BioPharma
Condition
Osteogenesis Imperfecta
Intervention
BPS804
Why stopped
Administrative Reason
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-03